Bio News

Bio.News is a daily online news platform that delves into the exciting world of biotechnology and how it interacts with both U.S. and global policies. Our team of independent journalists from various parts of the globe covers this rapidly evolving industry, highlighting how different levels of government can either promote or hinder biotech advancements and investments. Additionally, we provide insights from leading scientists and biotech executives, discussing ways to propel the biorevolution forward.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#3645202

United States

#1230680

Health/Biotechnology and Pharmaceuticals

#1155

Traffic sources

Monthly visitors

Articles

How cross-sector collaboration drives rare diseases cures

3 weeks ago | bio.news | Clary Estes

April is Sarocoidosis Awareness Month, an opportunity to raise awareness, promote understanding and research, and create hope for the affected patients and their families.
Sepsis and AMR: Understanding the connection and the growing threat to public health

1 month ago | bio.news | Clary Estes

As part of BIO’s March Patient Advocacy Coffee Chat, Thomas Heymann, President & CEO of Sepsis Alliance, spoke about sepsis—a life-threatening condition caused by the body’s immune system overreacting to an infection—and its link to rare diseases and antimicrobial resistance (AMR). Antimicrobial resistance—or AMR—occurs when the bacteria, viruses, or fungi that make people sick adapt to the antimicrobial medicines designed to treat them and become resistant to those medications.
Why reauthorization of the Rare Pediatric Disease Priority Review Voucher (PPRV) Program is vital

1 month ago | bio.news | Clary Estes

The Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher (PPRV) Program was top of mind during BIO’s March Patient Advocacy Coffee Chat: Show Your Stripes! The conversation brought together patient advocacy leaders and illustrated both the urgent need for incentives to support rare disease drug development and the power of patient advocacy.
International Women's Day: Improving women’s health by addressing autoimmune disease

1 month ago | bio.news | Clary Estes

March 8th is International Women’s Day and to mark the occasion, Bio.News is exploring an under researched field of women’s health – autoimmune diseases – with the Society for Women’s Health Research. Despite women making up half of the population, women’s health is still woefully researched and underfunded. This is not only to the detriment of women, but also to biotech innovation as a whole.
Kidney Action Week: 4 things you need to know about kidney disease

1 month ago | bio.news | Clary Estes

“Kidney disease is a major and growing public health concern,” LaVarne A. Burton, American Kidney Fund President and CEO, said in an interview with Bio.News.
The role of the patient voice in CMS drug price 'negotiation'

2 months ago | bio.news | Clary Estes

The Centers for Medicare & Medicaid Services (CMS) recently announced the 2025 selection of 15 drugs covered under Medicare Part D for price “negotiations” under the Inflation Reduction Act (IRA). The list covers many therapeutic areas, from diabetes and cancer to asthma, arthritis, and more.
Goodwin Rare Disease Symposium: 'So much opportunity, so much unmet need'

2 months ago | bio.news | Clary Estes

Drug development in the rare disease space has seen a vast amount of innovation in recent years, with a number of groundbreaking therapies coming to market. Yet, the unmet need remains high. “There are more than 10,000 rare diseases, and almost none of them have treatments,” said Karin Hoelzer, Senior Director of Patient Advocacy at the Biotechnology Innovation Organization (BIO) at the Goodwin Rare Disease Symposium on February 5 in Boston.
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs

2 months ago | bio.news | Clary Estes

The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any other treatment options. It allows for the approval of a treatment on the basis of an intermediate or surrogate endpoint that is reasonably likely to predict clinical benefit.
BIO CEO 2025: New solution for the challenge of schizophrenia

2 months ago | bio.news | Clary Estes

Despite a pressing demand, schizophrenia has had limited treatment. “Roughly 1% of the entire world population has schizophrenia,” said Boobalan Pachaiyappan, Managing Director and Senior Biotech Analyst at Roth Capital Partners, moderating a panel, Tackling Mental Health through New Targets and Endpoints Progress, during the 2025 Biotechnology Innovation Organization (BIO) CEO and Investor Conference.
BIO CEO 2025: AI is a tool - not magic

2 months ago | bio.news | Clary Estes

The idea of AI supercharging drug development is stirring a lot of excitement. However, a realistic understanding of what AI can and can’t do is important for anyone who wants to understand the innovation and investment potential, explained panelists at the 2025 Biotechnology Innovation Organization (BIO) CEO and Investor Conference in New York. The Feb.